As researchers continue to explore Alzheimer’s disease, they note that the immune system and disruptions in the brain-blood barrier can lead to its progression. The important brain-blood barrier is called the blood-cerebrospinal fluid (CSF) and, unfortunately, it is often neglected. Disruptions in the blood-CSF can negatively impact the progression of Alzheimer’s disease, but on the other hand, it may be blocked by a matrix metalloproteinase (MMP) inhibitor.
Roosmarijn Vandenbroucke from the Claude Libert Group said, “Although further research is needed, these data suggest that blocking MMP activity or upstream inflammatory signaling, might have therapeutic potential to treat Alzheimer’s disease. It is important we could demonstrate the role of the blood-cerebrospinal fluid barrier, because this would be an easier target to reach in comparison with the targets of current therapies.”
In Alzheimer’s disease the brain-blood barrier crumbles, but little is known as to how or why this occurs. The study sheds some light as to why this occurs.